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ARTICLE
LSD1-mediated enhancer silencing attenuates
retinoic acid signalling during pancreatic endocrine
cell development
Nicholas K. Vinckier1,6, Nisha A. Patel1,6, Ryan J. Geusz 1,6, Allen Wang1, Jinzhao Wang 1, Ileana Matta1,
Austin R. Harrington1, Matthew Wortham1, Nichole Wetton1, Jianxun Wang2, Ulupi S. Jhala3,
Michael G. Rosenfeld 2, Christopher W. Benner 4, Hung-Ping Shih 5 & Maike Sander 1✉
Developmental progression depends on temporally defined changes in gene expression
mediated by transient exposure of lineage intermediates to signals in the progenitor niche. To
determine whether cell-intrinsic epigenetic mechanisms contribute to signal-induced tran-
scriptional responses, here we manipulate the signalling environment and activity of the
histone demethylase LSD1 during differentiation of hESC-gut tube intermediates into pan-
creatic endocrine cells. We identify a transient requirement for LSD1 in endocrine cell dif-
ferentiation spanning a short time-window early in pancreas development, a phenotype we
reproduced in mice. Examination of enhancer and transcriptome landscapes revealed that
LSD1 silences transiently active retinoic acid (RA)-induced enhancers and their target genes.
Furthermore, prolonged RA exposure phenocopies LSD1 inhibition, suggesting that LSD1
regulates endocrine cell differentiation by limiting the duration of RA signalling. Our findings
identify LSD1-mediated enhancer silencing as a cell-intrinsic epigenetic feedback mechanism
by which the duration of the transcriptional response to a developmental signal is limited.
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During development, intermediate progenitors progresstoward a distinct cell fate as a result of sequentialinstructions by signalling cues in the progenitor niche.
The duration of a developmental signal has to be limited in order
for developmental intermediates to appropriately respond to the
next inductive cue. For example, pancreas induction from the
foregut endoderm requires retinoic acid (RA) signalling, but
thereafter RA signalling activity needs to be dampened for pan-
creatic progenitors to correctly interpret pro-endocrine differ-
entiation cues1. Thus, signalling cues are interpreted in a highly
context-dependent manner and signals need to be temporally
limited to delineate critical competence windows for develop-
mental transitions. An open question is whether removal of the
signal is sufficient to terminate a response to a signal or whether
cell-intrinsic mechanisms at the level of the responder tissue
enable developmental transitions by limiting the duration of
signal-induced transcriptional responses.
Spatiotemporal gene expression during development is regulated
by transcriptional enhancers2. Chromatin state at enhancers is a
significant determinant of transcriptional responsiveness to envir-
onmental signals, and enhancers respond to signalling cues by
modifying their chromatin state. Enhancers can exhibit an inactive,
poised, or active chromatin state. Inactive enhancers are char-
acterised by compact chromatin and absence of active histone
modifications, whereas poised enhancers are nucleosome-free and
marked by mono- and di-methylation of histone H3 at lysine 4
(H3K4me1 and H3K4me2)3–5. The transition from an inactive to a
poised enhancer state during development coincides with a gain in
cellular competence of lineage intermediates to respond to inductive
signalling cues5. Thus, developmental competence can be defined as
a temporal state during which the epigenetic landscape is permissive
for responding to environmental signals. Signal-dependent tran-
scription factors (TFs) activate poised enhancers by recruiting co-
activator complexes containing histone acetyltransferases (HATs)
that deposit H3K27 acetylation (H3K27ac) marks, thereby trans-
forming the poised enhancer into one that actively supports tran-
scription6. It is unknown whether or not the erasure of these
epigenetic marks is a prerequisite for termination of one compe-
tence window and transition to the next.
Lysine-specific demethylase 1 (LSD1), also known as KDM1A,
regulates chromatin by catalysing the removal of mono- and di-
methyl marks from K4 at histone H37, thus rendering poised
enhancer chromatin inactive8. This process has been called
enhancer decommissioning and is coupled to complete silencing
of associated genes8. Despite its role in enhancer silencing, LSD1
frequently resides in complexes of active enhancers9–11. In the
context of acetylated histones, LSD1 activity and demethylation of
H3K4 is inhibited9. Therefore, current evidence suggests that
histones need to be deacetylated before LSD1 can decommission
active enhancers. Consistent with this mechanism, LSD1 occupies
enhancers of pluripotency genes in pluripotent stem cells and
decommissions these enhancers only when pluripotent stem cells
undergo differentiation8. Whether LSD1-mediated regulation of
enhancer chromatin plays a role in defining developmental
competence windows and enabling sequential cell state transi-
tions remains unknown.
Here, we ask whether epigenetic mechanisms can limit the
duration of an inductive signal throughout a developmental time
course, thereby defining distinct competence windows and pre-
venting inappropriate responses to developmental signals. To
investigate this, we manipulate LSD1 activity and RA signalling in a
human embryonic stem cell (hESC)-based differentiation system,
where cells progress stepwise in defined conditions toward the
pancreatic endocrine cell fate. We show that LSD1-mediated
enhancer decommissioning limits the time window during which
cells express RA-induced genes. When LSD1 activity is inhibited
immediately after pancreas induction, RA-induced genes fail to be
silenced despite removal of RA as an inductive signal, which is
associated with an inability of the cells to undergo endocrine cell
differentiation. Thus, our results show that loss of LSD1 function
critically alters the epigenetic landscape that terminates the com-
petence window for RA signalling. These findings identify mod-
ification of the epigenome as an important cell-intrinsic mechanism
for sharpening transcriptional responses to developmental signals.
Results
Human pancreatic endocrine cell development requires LSD1.
To investigate possible roles for LSD1 during defined windows of
transition to a differentiated cell type, we employed a hESC dif-
ferentiation system, in which cells progress stepwise toward the
pancreatic endocrine cell lineage through sequential exposure to
signalling cues that guide corresponding cell state transitions in
the developing embryo (Fig. 1a)5,12–14. In this differentiation
system, LSD1 was broadly expressed throughout progression to
the endocrine cell stage (EN) (Supplementary Fig. 1a, b). Like-
wise, levels of flavin adenine dinucleotide (FAD), which is a
metabolic cofactor of LSD115, did not change substantially
throughout the differentiation time course (Supplementary
Fig. 1c). We verified LSD1 expression in pancreatic progenitor
cells and differentiated endocrine cells in human foetal and adult
tissue (Supplementary Fig. 1d).
To assess whether LSD1 is required for pancreatic develop-
ment, we started by blocking LSD1 activity immediately after the
initiation of pancreas induction during the transition from the
early (PP1) to the late (PP2) pancreatic progenitor cell stage
(LSD1iearly), using the irreversible LSD1 inhibitor tranylcypro-
mine (TCP) (Fig. 1a). PP1 and PP2 progenitors are distinguished
by increasing expression of pancreatic TFs that commit
progenitors to the endocrine cell fate, including NKX6.1 and
NGN312. Thus, PP1 cells represent a less committed pancreatic
progenitor cell stage, whereas PP2 cells exhibit features of
endocrine cell commitment. LSD1 inhibition during the PP1 to
PP2 transition did not negatively affect expression of PDX1,
NKX6.1, or NGN3 (Supplementary Fig. 1e–h), indicating that
endocrine-committed pancreatic progenitors can form in the
absence of LSD1. However, when LSD1iearly cells were further
differentiated to the EN stage, we observed a striking absence of
endocrine cells at the EN stage, while progenitor cell markers
remained largely unaffected (Fig. 1b–d and Supplementary Fig. 2).
The same phenotype was observed when culturing in the
presence of several other irreversible and reversible LSD1
inhibitors during the PP1 to PP2 transition or by transducing
cells with a lentivirus expressing shRNAs for LSD1 a day prior to
the PP1 stage (Supplementary Figs. 3a–d and 4a–c). The normal
progression through endocrine commitment but the absence of
endocrine cells after LSD1 inhibition indicated a specific
requirement for LSD1 activity during endocrine cell differentia-
tion. To directly test whether the endocrine cell differentiation
step requires LSD1 activity, we added TCP or the LSD1 inhibitor
GSK2879552 during the PP2 to EN transition (LSD1ilate).
Surprisingly, this later inhibition of LSD1 did not perturb
endocrine cell formation (Fig. 1b–d and Supplementary Fig. 3b-
d). Thus, endocrine cell development requires LSD1 activity
during a narrow time window after pancreas induction, but not
during endocrine cell differentiation. This indicates that LSD1-
mediated changes during the PP1 to PP2 transition affect the
ability of developmental precursors to undergo endocrine
differentiation later in development.
LSD1 inhibition prevents enhancer silencing. Given LSD1’s role
as a chromatin modifier7, we investigated whether loss of LSD1
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activity during the PP1 to PP2 transition could block endocrine cell
development due to aberrant regulation of the epigenome. To this
end, we performed chromatin immunoprecipitation sequencing
(ChIP-seq) for LSD1 at the PP1 stage and mapped chromatin state
changes at LSD1-bound sites during the PP1 to PP2 transition
without and with LSD1 inhibition. We identified a total of 15,084
LSD1 peaks at the PP1 stage throughout the genome (Supple-
mentary Fig. 5a and Supplementary Data 1, 2). Of these, the vast
majority were promoter-distal (11,799; >3 kb from TSS; Supple-
mentary Fig. 5a and Supplementary Data 2), which is consistent
with prior observations in hESCs8. Distal LSD1 peaks at PP1
overlapped with binding sites for the early pancreatic TFs FOXA1,
FOXA2, GATA4, GATA6, and HNF6, suggesting that these TFs
reside in a complex with LSD1 (Supplementary Fig. 5b,c).
Distal enhancers are highly dynamic during pancreatic
development5, leading us to postulate that LSD1 controls
endocrine cell differentiation by regulating changes in enhancer
chromatin state during the PP1 to PP2 transition. To test this, we
performed ChIP-seq for the active enhancer mark H3K27ac4,16,17
at the PP1 and PP2 stage. Reasoning that effects of LSD1 on the
active enhancer landscape would be most likely to affect gene
expression and therefore have high propensity to be causal for the
phenotype, we isolated enhancers that are active at PP1 and/or
PP2 and also bound by LSD1 at the PP1 stage. This analysis
revealed three groups of LSD1-bound enhancers: Group 1 (G1)
enhancers (n= 1345) underwent deactivation during the PP1 to
PP2 transition (≥2-fold decrease in H3K27ac); Group 2 (G2)
enhancers (n= 765) were active at both PP1 and PP2 (<2-fold
change in H3K27ac); and Group 3 (G3) (n= 511) enhancers
underwent activation (≥2-fold increase in H3K27ac) during the
PP1 to PP2 transition (Fig. 2a and Supplementary Data 3–5). We
next examined the “poised” chromatin modifications H3K4me1
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Fig. 1 Endocrine cell formation requires LSD1 activity during a short window in early pancreatic development. a Schematic of the human embryonic
stem cell (hESC) differentiation protocol to the endocrine cell stage (EN) and experimental plan for LSD1 inhibition. b Immunofluorescent staining for
pancreatic hormones insulin (INS), glucagon (GCG) and somatostatin (SST) or PDX1 and NKX6.1 in control EN cells compared to EN cells with early
(LSD1iearly) and late (LSD1ilate) LSD1 inhibition (representative images, n= 10 independent differentiations). Scale bar, 50 µm. c qRT-PCR analysis for INS,
GCG and SST in control, LSD1iearly and LSD1ilate EN cells. Data are shown as mean ± S.E.M. (n= 3 replicates from independent differentiations with n= 3
technical replicates per sample; source data are provided as a Source Data file). P= 7.93 e−4, 1.42 e−2, 2.32 e−4, 8.71 e−4, 3.5 e−2, and 1.52 e−3,
respectively, Student’s t-test, 2 sided. d Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control, LSD1iearly and LSD1ilate cells.
Isotype control for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated
(representative experiment, n= 2 independent differentiations). D, day; AA, activin A; ITS, insulin-transferrin-selenium; TGFBi, TGFβ R1 kinase inhibitor;
KC, KAAD-cyclopamine; KGF, keratinocyte growth factor; RA, retinoic acid; EGF, epidermal growth factor; ES, human embryonic stem cells; DE, definitive
endoderm; GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors; EN, endocrine cell stage; FSC-A, forward scatter area.
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and H3K4me2 at these three enhancer groups during the PP1 to
PP2 transition. We observed that LSD1-bound G1 enhancers
exhibited a marked decrease in H3K4me1 and H3K4me2 (Fig. 2b),
consistent with known roles of LSD1 as a H3K4me2 and
H3K4me1 demethylase7,18. Thus, G1 enhancers are decommis-
sioned during the PP1 to PP2 transition. To investigate whether
LSD1 recruitment is regulated at these decommissioned enhan-
cers, we examined LSD1 occupancy also in gut tube (GT) and
PP2 cells. At G1 enhancers, we observed an increase in LSD1
ChIP-seq signal from GT to PP1 and a decrease from PP1 to PP2,
whereas LSD1 signal was similar at all stages in the G2 and G3
enhancer groups (Fig. 2c). Since endocrine cell development
requires LSD1 activity during the PP1 to PP2, but not the PP2 to
EN transition, the transient recruitment of LSD1 to G1 enhancers
at the PP1 stage could signify a specific importance of this
enhancer group for the endocrine differentiation phenotype.
To determine whether LSD1 activity is required for remodel-
ling enhancer chromatin during the PP1 to PP2 transition, we
analysed H3K27ac, H3K4me2 and H3K4me1 modifications in
PP2 cells after LSD1 inhibition (LSD1iearly). In all three enhancer
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clusters, we observed little effect of LSD1 inhibition on H3K27ac
dynamics during the PP1 to PP2 transition (Fig. 2d, e and
Supplementary Fig. 5d). The activation (i.e. acetylation) of G1
enhancers coincided with the pancreas induction step from GT to
PP1 (Fig. 2d, e and Supplementary Fig. 5e). Confirming our prior
observation that pancreas-specific enhancers are poised prior to
activation5, G1 enhancers exhibited significant deposition of
H3K4me1 at the GT stage (Fig. 2d). Thus, G1 enhancers become
activated during pancreas induction and are quickly fully
inactivated (i.e. decommissioned) as pancreatic endocrine devel-
opment proceeds. Consistent with LSD1’s enzymatic activity,
LSD1 inhibition during the PP1 to PP2 transition led to
significant accumulation of H3K4me1 and H3K4me2, particularly
at G1 enhancers (Fig. 2d, e and Supplementary Fig. 5e; p < 2.2e
−16, Wilcoxon rank-sum test). H3K4me1 and H3K4me2 levels at
G1 enhancers in LSD1iearly PP2 cells were similar to levels at PP1,
showing a requirement for LSD1 in decommissioning these
enhancers during the PP1 to PP2 transition. Although H3K4me1
and H3K4me2 levels were also increased at G2 and G3 enhancers
after LSD1 inhibition, the effect was less pronounced compared to
G1 enhancers (Supplementary Fig. 5d). Importantly, H3K4me1
and H3K4me2 deposition was not increased at enhancers not
bound by LSD1 (Supplementary Fig. 5f and Supplementary
Data 6), demonstrating specificity of the effect to LSD1-bound
enhancers. Combined, this analysis identified a LSD1-regulated
set of enhancers that is activated upon addition of pancreas-
inductive factors during the GT to PP1 transition and
deacetylated and decommissioned (i.e. demethylated) when these
factors are withdrawn from PP1 to PP2 (Fig. 2f). We find that
deacetylation of these enhancers occurs largely independent of
LSD1, but that LSD1 is required for enhancer decommissioning
and thus complete enhancer silencing. Given prior findings that
LSD1 activity is inhibited in context of acetylated histones9, these
results suggest that histone acetylation from GT to PP1 prevents
LSD1-mediated enhancer silencing and that LSD1-independent
H3K27ac removal allows LSD1 to silence these enhancers during
the PP1 to PP2 transition.
LSD1 represses retinoic acid-dependent genes. We next sought
to investigate possible effects of the observed chromatin changes
on gene expression and compared RNA-seq profiles of control
PP2 cells and PP2 cells after LSD1 inhibition (LSD1iearly). This
analysis identified 445 genes that decreased and 955 genes that
increased in expression due to LSD1 inhibition (Fig. 3a and
Supplementary Data 7 and 8; p < 0.05, ≥1.5-fold change). To
identify those genes most likely directly regulated by LSD1, we
performed enrichment analysis for G1, G2, and G3 enhancers as
well as other distal LSD1 binding sites near genes up- and
downregulated after LSD1 inhibition (TSS ± 100 kb from LSD1
peak). G1, G2, and G3 enhancers, but not other distal LSD1
binding sites, showed significant enrichment close to genes
upregulated due to LSD1 inhibition (Fig. 3b and Supplementary
Data 3–6). The majority of the enhancer-associated upregulated
genes were near G1 enhancers (Fig. 3c). By contrast, we observed
significant depletion or lack of enrichment of distal LSD1-bound
sites near genes downregulated in LSD1iearly cells (Supplementary
Fig. 6a). Together, this analysis suggests that direct LSD1 target
genes are overrepresented among genes upregulated after LSD1
inhibition, whereas downregulated genes are not directly LSD1-
regulated.
We next determined how candidate G1, G2 and G3 enhancer
target genes (Supplementary Data 9–11) are regulated over
the developmental time course (Fig. 3d and Supplementary
Fig. 6b, c). G1 enhancer-associated genes that were upregulated
by LSD1 inhibition were induced during the GT to PP1 transition
and then downregulated during the transition to PP2 (Fig. 3d).
Thus, the expression pattern of G1 enhancer-associated, LSD1-
regulated genes mirrors the acetylation pattern of G1 enhancers,
which are not acetylated at the GT stage, acetylated at the
PP1 stage, and LSD1-dependently decommissioned during the
PP1 to PP2 transition (Fig. 2d). Unbiased analysis of over-
represented pathways among genes upregulated by LSD1
inhibition revealed enrichment for genes linked to RA signalling
in the G1, but not G2 or G3, enhancer-associated group of genes,
suggesting an important role for RA signalling in the regulation of
G1 enhancer-associated genes (Fig. 3e, Supplementary Fig. 6b, c
and Supplementary Data 12–14). To simulate the requirement for
RA signalling in pancreatic lineage induction in vivo19,20, RA is
one of three growth factors added to the culture medium during
the GT to PP1 transition to induce pancreatic genes (Fig. 1a)12.
RA is subsequently withdrawn during the transition from PP1 to
PP2. During the PP1 to PP2 transition, the only possible source
for stimulation of the RA receptor (RAR) are traces of retinol in
the B27 supplement. Thus, the activity of G1 enhancers and
expression of associated genes precisely coincides with the
addition and removal of exogenous RA.
Prolonged retinoic acid exposure phenocopies LSD1 inhibi-
tion. RA regulates gene expression by binding to its hetero-
dimeric receptor composed of RAR and retinoid X receptor
(RXR)21. In the absence of RA, the RAR/RXR heterodimer
recruits co-repressors leading to histone deacetylation and gene
silencing, while RA binding to RAR/RXR induces recruitment of
HATs, mediating histone acetylation and activation of RA-
dependent genes. Hence, the observed pattern of H3K27 acet-
ylation at G1 enhancers during progression from GT to PP2
(Fig. 2d) is consistent with RA-dependent regulation of these
enhancers. To determine whether G1 enhancers are indeed
Fig. 2 LSD1 inhibition prevents decommissioning of transiently active early pancreatic enhancers. a Heatmap showing density of ChIP-seq reads for
LSD1 and H3K27ac centred on LSD1 peaks, spanning 10 kb. G1, G2 and G3 groups of LSD1-bound enhancers are deactivated (G1; n= 1345), remain active
(G2; n= 765), or are activated (G3; n= 511) from PP1 to PP2. b Box plots of H3K4me1 and H3K4me2 ChIP-seq counts at G1, G2 and G3 enhancers at PP1
and PP2 stages. Plots are centred on median, with box encompassing 25th–75th percentile and whiskers extending up to 1.5 interquartile range (Tukey
style). P= 5.0 e−12, < 2.2 e−16, <2.2 e−16, 1.73 e−2, <2.2 e−16, and 8.23 e−14, respectively, Wilcoxon rank-sum test, 2 sided. c Tag density plots
displaying LSD1 tag distribution at G1, G2 and G3 enhancers at GT, PP1 and PP2 stages, centred on PP1 LSD1 peaks. d Tag density plots (left) for G1
enhancers displaying H3K27ac, H3K4me2 and H3K4me1 tag distribution at GT and PP1 stages, and at PP2 stage with and without early LSD1 inhibition
(TCP, LSD1iearly). Plots are centred on PP1 LSD1 peaks. Box plots (right) of H3K27ac, H3K4me2 and H3K4me1 ChIP-seq counts at G1 enhancers at
PP2 stage with and without early LSD1 inhibition (LSD1iearly). Plots are centred on median, with box encompassing 25th–75th percentile and whiskers
extending up to 1.5 interquartile range (Tukey style). P= 4.59 e−5, <2.2 e−16, and <2.2 e−16, respectively, Wilcoxon rank-sum test, 2 sided. e LSD1,
H3K4me2, and H3K27ac ChIP-seq profiles at an enhancer near HOXA1. fModel for LSD1-dependent enhancer decommissioning. Enhancer deactivation by
removal of acetylation from H3K27 occurs independent of LSD1 activity. LSD1 subsequently mediates enhancer decommissioning by removal of H3K4me2
marks. KC, KAAD-cyclopamine; KGF, keratinocyte growth factor; RA, retinoic acid; EGF, epidermal growth factor. GT, primitive gut tube; PP1, early
pancreatic progenitors; PP2, late pancreatic progenitors. All ChIP-seq experiments, n= 2 replicates from independent differentiations.
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regulated by RA, we performed TF binding motif enrichment
analysis. This analysis revealed significant enrichment of the
motif for the RAR/RXR heterodimer at G1 compared to G2 and
G3 enhancers (Fig. 4a and Supplementary Data 15). When motifs
at G2 and G3 enhancers were compared against the entire gen-
ome, excluding G1, G2, and G3 regions, no RAR/RXR motif
enrichment was observed, further supporting specific enrichment
of the RAR/RXR motif at G1 enhancers (Supplementary Data 16).
ChIP-seq analysis for RXR, which is the obligatory binding
partner for all RAR isoforms, confirmed RXR binding to G1
enhancers at the PP1 stage (Fig. 4b, Supplementary Fig. 5c and
Supplementary Data 17). RXR binding was enriched at G1
enhancers when compared to either G2 or G3 enhancers (Fisher’s
exact test, p= 1.728 e−8 and p= 9.427 e−15, respectively),
indicating RA-dependent regulation particularly of G1 enhancers.
To determine whether failure to silence RA-induced genes
could be the mechanism by which LSD1 inhibition blocks
endocrine cell differentiation, we tested whether extended RA
exposure of pancreatic progenitors abrogates endocrine cell
differentiation in a similar manner as LSD1 inhibition. To extend
the time period of RA signalling, we added the RA analogue
TTNPB not only from the GT to PP1 stage, but also during the
PP1 to PP2 transition (Fig. 4c, RAextended) and then differentiated
RAextended cultures to the EN stage. Mimicking the LSD1iearly
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phenotype, EN stage RAextended cultures exhibited a striking
absence of endocrine cells, while the progenitor cell markers
PDX1, NKX6.1, and NGN3 were unaffected (Fig. 4d, e and
Supplementary Fig. 7a–d). Thus, RA exposure of pancreatic
progenitors has to be transient for endocrine cell differentiation
to occur.
We next employed RNA-seq analysis to identify genes
dysregulated as a result of prolonged RA exposure. Only 96
genes were downregulated and 69 upregulated in RAextended PP2
cultures (Fig. 4f and Supplementary Data 18 and 19; p < 0.05,
≥1.5-fold change), suggesting that the endocrine differentiation
block is mediated by dysregulation of a modest number of genes.
Consistent with the small number of dysregulated genes in
RAextended cells compared to LSD1iearly cells, RAextended cells
more closely resembled untreated PP2 cells than LSD1iearly cells
(Supplementary Fig. 6e). Strikingly, genes upregulated after LSD1
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inhibition were significantly enriched among the genes also
increased in expression after prolonged RA exposure (Fig. 4f),
and genes near G1 enhancers largely accounted for this
enrichment (Fig. 4g). Genes downregulated after LSD1 inhibition
were likewise enriched among genes decreased in expression after
prolonged RA, but LSD1-occupied enhancers were not enriched
in the vicinity of these genes (Supplementary Fig. 7f), suggesting
indirect effects. Among the genes upregulated by both LSD1
inhibition and prolonged RA exposure were numerous genes
known to be regulated by RA, including genes encoding HOX
TFs and RA-inactivating enzymes of the CYP26 family (Fig. 4h),
supporting the notion that RA-induced genes need to be silenced
for cells to acquire competence for endocrine cell differentiation.
Together, our findings support a model whereby LSD1 silences
RA-regulated genes by decommissioning their enhancers upon
RA withdrawal, thereby ensuring transient, ligand-dependent
expression of RA-induced genes. Under conditions of prolonged
RA exposure, RA-mediated recruitment of HATs maintains
histone acetylation21, which inhibits LSD1 activity9 and prevents
enhancer decommissioning during the PP1 to PP2 transition.
LSD1 dampens future responses to retinoic acid. We sought to
further substantiate that LSD1 regulates RA responsiveness and
that the block in endocrine cell differentiation after LSD1 inhi-
bition is linked to aberrant expression of RA-dependent genes.
We predicted that endocrine cell differentiation should not be
perturbed when cells are re-exposed to RA during the PP2 to EN
transition, because enhancers of early RA-responsive genes are
already decommissioned at the PP2 stage (Fig. 2d, e and Sup-
plementary Fig. 5d). To test this, we re-introduced RA into the
culture medium during the PP2 to EN transition (RAlate; Fig. 5a).
As hypothesised, and in stark contrast to RAextended cultures
(Fig. 4d, e), endocrine cells were present in RAlate EN stage cul-
tures in numbers almost identical to control cultures (Fig. 5b, c
and Supplementary Fig 8a, b). Thus, similar to addition of the
LSD1 inhibitor (Fig. 1a–d), addition of RA prevents endocrine
cell formation only during the PP1 to PP2 but not the PP2 to EN
transition.
To further test whether enhancer decommissioning is a
mechanism by which to regulate RA responsiveness, we re-
exposed cells to RA from PP2 to EN (RAlate) with or without
prior LSD1 inhibition during the PP1 to PP2 transition (Fig. 5a).
As expected, LSD1iearly+ RAlate treatment completely blocked
endocrine cell differentiation, phenocopying LSD1iearly cultures
(Supplementary Fig. 8c, d). To determine whether prior LSD1
inhibition alters the extent to which RA-regulated genes can be
induced by RA, we measured gene expression changes in
response to RA. To this end, we compared gene expression at
the EN stage in LSD1iearly vs. LSD1iearly+ RAlate and control vs.
RAlate conditions. We used LSD1iearly EN cells, rather than
control EN stage cultures, as a reference for the cells re-exposed
to RA after LSD1iearly treatment to control for the population bias
caused by the lack of endocrine cells after LSD1 inhibition. Most
genes near G1 enhancers that are upregulated by both LSD1
inhibition (Fig. 3a) and extended RA exposure (Fig. 4f), including
HOXA1, HOXA3, HOXC4, and CYP26B1, exhibited a higher
degree of inducibility by RA with prior LSD1 inhibition (Fig. 5d,
Supplementary Fig. 8e and Supplementary Data 20 and 21). Thus,
LSD1 appears to dampen, although not obliterate, future RA
responsiveness in cells that have been previously exposed to RA.
We observed no difference in the expression of LSD1, RARs, or
RXRs between the different conditions (Supplementary Fig. 8f),
indicating that alteration of the epigenetic state rather than
differences in TF and co-factor expression explain the heightened
RA responsiveness after LSD1 inhibition. We note that other
factors must also control RA responsiveness since HOXA1,
HOXA3, HOXC4, CYP26A1, and CYP26B1 are still induced by
late RA treatment without prior LSD1 inhibition.
Lsd1 is required for endocrine cell development in vivo. To
verify our in vitro findings in an in vivo model, we deleted Lsd1
conditionally in mice to determine whether endocrine cell dif-
ferentiation requires Lsd1 activity transiently in early pancreas
development, as observed in the hESC differentiation system. As
in the human pancreas (Supplementary Fig. 1d), Lsd1 was highly
expressed in pancreatic progenitors and endocrine cells (Sup-
plementary Fig. 9a, b). To selectively inactivate Lsd1 in early
pancreatic progenitors similar to LSD1 inhibition at PP1, we
generated Pdx1Cre;Lsd1flox/flox (Lsd1Δpan) mice (Fig. 6a). In
Lsd1Δpan embryos, key aspects of early pancreatic development,
such as the induction of early pancreatic markers and outgrowth
of the tissue buds, were unperturbed (Fig. 6b, c and Supple-
mentary Fig. 9c). However, by embryonic day (e) 15.5, when
widespread endocrine cell differentiation was evident in control
mice, Lsd1Δpan embryos exhibited an almost complete lack of
endocrine cells (Fig. 6b), a phenotype that remained apparent at
postnatal day (P) 0 (Fig. 6b, d). In vivo inactivation of Lsd1
further revealed that Lsd1 activity is selectively required for the
development of the endocrine lineage, while being dispensable for
exocrine cell formation and key aspects of early pancreatic
development, such as maintenance of pancreatic progenitors and
growth of the developing organ (Fig. 6b, c and Supplementary
Fig. 4 Prolonged retinoic acid exposure of early pancreatic progenitor cells phenocopies LSD1 inhibition. a Enriched transcription factor (TF) binding
motifs with associated p-values for G1 enhancers compared to G2 and G3 enhancers. Fisher’s exact test, 2 sided, corrected for multiple comparisons.
b Enrichment for RXR peaks (±1 kb) among G1 enhancers versus random genomic regions. P= 0, permutation test. c Experimental plan to extend retinoic
acid (RA) exposure through PP1 to PP2 (RAextended) during hESC differentiation to the endocrine cell stage (EN). d Immunofluorescent staining for insulin
(INS), glucagon (GCG) and somatostatin (SST) in control EN cells compared to EN cells with extended RA treatment (RAextended) (representative images,
n= 3 independent differentiations). Scale bar, 50 µm. e Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control and RAextended
cultures. Isotype control for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated
(representative experiment, n= 2 independent differentiations). f Volcano plot of differentially expressed genes at PP2 in RAextended cultures. Differential
expression calculated with DESeq2 and genes with ≥1.5-fold change up or down. Adjusted p-values < 0.05 were considered differentially expressed. 96
genes were downregulated and 69 were upregulated in RAextended cultures. Black dots indicate genes not significantly changed (p-value > 0.05), grey dots
genes significantly changed (p-value < 0.05) but less than 1.5-fold compared to control, red and green dots genes significantly up- and downregulated
(p-value < 0.05 and ≥ 1.5-fold change), respectively. Yellow dots highlight genes also upregulated after LSD1 inhibition from PP1 to PP2 (TCP, LSD1iearly)
(n= 2 replicates from independent differentiations). g Enrichment analysis of genes associated with LSD1-bound enhancers and upregulated by LSD1iearly
among those upregulated by RAextended. Dashed line indicates p-value= 0.05, Fisher’s exact test, 2 sided. h mRNA levels of select genes significantly
upregulated in both LSD1iearly and RAextended PP2 cells. Levels at PP1 stage are also displayed. Data shown as mean FPKM± S.E.M. (n= 2 replicates from
independent differentiations; source data are provided as a Source Data file). GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic
progenitors.
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Fig. 9c–e). Analysis of the endocrine progenitor marker Ngn3
further revealed that endocrine lineage commitment was unaf-
fected in Lsd1Δpan embryos (Fig. 6b, c). Thus, as in the hESC
differentiation system, Lsd1 inactivation in early pancreatic pro-
genitors of mice prevents endocrine cell differentiation after
endocrine fate commitment.
To determine when precisely Lsd1 is required for endocrine
cell development, we crossed Lsd1flox/flox and Pdx1CreERTM mice,
allowing for temporally controlled Lsd1 inactivation in pancreatic
progenitors by tamoxifen administration (Fig. 6e). Consistent
with the phenotype of Lsd1Δpan mice, tamoxifen administration
at e10.5 (Lsd1Δearly mice) resulted in almost complete absence of
endocrine cells (Fig. 6f and Supplementary Fig. 9f). Remaining
endocrine cells in Lsd1Δearly mice were mostly Lsd1+ due to
mosaic deletion (Supplementary Fig. 9f, g). By contrast,
tamoxifen injection at e12.5 (Lsd1Δlate mice), which targets late
pancreatic progenitors shortly before endocrine cell differentia-
tion similar to PP2 cells, did not affect endocrine cell formation,
as evidenced by the presence of Lsd1-deficient hormone+ cell
clusters (Fig. 6f and Supplementary Fig. 9g). Therefore, as in the
hESC differentiation system, endocrine cell differentiation in
mice requires Lsd1 activity during a narrow time window in early
pancreas development. Furthermore, early pancreatic inactivation
of Lsd1 resulted in up-regulation of HoxA1 transcripts (Fig. 6g) as
observed in hESC-PP2 cells (Fig. 3a). Combined our in vitro and
in vivo findings support a model whereby LSD1 controls
progression to the endocrine cell stage by limiting the duration
of early RA signalling through chromatin modification at RA-
responsive enhancers.
Discussion
Proper formation of terminally differentiated cell types requires
precise timing, amplitude, and, as suggested by this study, dura-
tion of developmental signals. Our findings show that decom-
missioning (i.e. complete inactivation) of RA-dependent early
pancreatic enhancers temporally limits the expression of RA-
induced genes after RA is removed, thereby creating a sharp and
transient gene expression response to RA. This mechanism can
explain how the duration of a transcriptional response to a
transient inductive signal is limited during a developmental time
course. Furthermore, we observed that enhancer decommission-
ing dampens future gene inducibility by the same signal. Our
findings suggest that developmental competence windows are
terminated through erasure of epigenetic marks, providing a
mechanistic understanding of why developmental signals evoke
context-dependent cellular responses. Underscoring the impor-
tance of enhancer silencing for developmental progression, we
find that the inability to decommission RA-dependent enhancers
and down-regulate RA-induced genes coincides with subsequent
failure to initiate endocrine cell differentiation. We propose that
LSD1-mediated enhancer decommissioning is a responder tissue-
intrinsic mechanism by which perduring transcriptional effects of
transient developmental signals are prevented. By helping close
competence windows during rapid developmental transitions,
this mechanism could help create a conducive state for correct
interpretation of the next inductive signal.
Our findings indicate that LSD1-mediated silencing of a subset
of RA-dependent early pancreatic genes is necessary for
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pancreatic progenitors to acquire competence for endocrine cell
differentiation. We identified a set of LSD1-regulated genes,
including many HOX genes and other genes known to be directly
regulated by RA, that are transiently expressed after pancreas
induction and quickly downregulated as cells transition to an
endocrine-committed pancreatic progenitor cell state, marked by
NKX6.1 and NGN3. Several observations suggest that the
mechanism by which LSD1 controls endocrine cell development
is to silence these RA-regulated genes prior to endocrine cell
differentiation. First, we observed that endocrine cell formation in
both the hESC-based system and in mice proceeds normally
when LSD1 is inhibited or deleted during endocrine cell differ-
entiation, implying that LSD1 has no immediate role in the
activation of endocrine genes. Second, like LSD1 inhibition,
extended exposure of uncommitted hESC-pancreatic progenitors
to RA blocks endocrine cell differentiation, whereas RA exposure
during endocrine cell differentiation does not. Similarly, exposure
of mouse embryonic pancreatic explants to high RA concentra-
tions prior to endocrine cell differentiation has been shown to
impair endocrine cell formation22. Furthermore, we showed that
after both early LSD1 inhibition and extended RA exposure of
hESC-pancreatic progenitors, RA-induced genes are upregulated,
which indicates that dysregulation of these genes is relevant for
the phenotype. Third, Lsd1 deletion in pancreatic progenitors of
mice has no overt effect on exocrine cell differentiation or other
aspects of pancreatic development, suggesting that Lsd1-mediated
silencing of these RA-regulated genes occurs specifically during
endocrine lineage progression. Consistent with this notion, the
expression of HOXA1 is maintained in pancreatic exocrine
cells23. Similar to pancreas development, LSD1 is expressed in the
developing nervous system and plays an important role in neural
differentiation24,25. Given that RA has time-dependent roles
during different phases of neural development26, it is possible that
a similar connection between LSD1 and the regulation of RA
signalling windows exists during neurogenesis.
Our findings suggest that the presence of LSD1 in enhancer
complexes enables silencing of RA-induced genes after the
withdrawal of exogenous RA. In the context of LSD1 inhibition,
silencing of RA-dependent genes does not occur despite RA
removal, showing that absence of the RA signal is not sufficient
for gene inactivation. RA is known to maintain histone acetyla-
tion by mediating recruitment of HATs, while removal of RA
results in a co-factor switch leading to histone deacetylation21.
Because presence of acetylated histones inhibits LSD1 activity9,
LSD1-mediated enhancer decommissioning is prevented as long
as RA is present, linking enhancer decommissioning and target
gene silencing to RA withdrawal. Thus, presence of LSD1 in
enhancer complexes provides a cell-intrinsic epigenetic mechan-
ism that couples the duration of gene expression to the presence
of the extrinsic signal. It is possible that LSD1 at promoters also
contributes to gene regulation after LSD1 inhibition. However,
TSSs of the majority of RA-induced genes that were upregulated
after LSD1 inhibition (e.g. HOXA1, HOXA3, HOXC4, CYP26A1,
CYP26B1) were not LSD1-bound (Supplementary Data 1), sug-
gesting that effects on gene expression are mediated by distal
enhancers.
We show that inhibition of LSD1 activity during develop-
mental progression coincides with increased H3K4me2/me1
deposition and increased expression of RA-dependent genes after
RA removal. This raises the question of whether the catalytic
activity of LSD1 and increased H3K4me2/me1 levels or
demethylase-independent functions of LSD1 are responsible for
the increased expression of RA-dependent genes. Our data sug-
gest that the catalytic activity of LSD1 is indeed important,
because TCP and other LSD1 inhibitors inhibit LSD1’s catalytic
activity. Of note, a recent study in ESCs showed that H3K4me1 is
not required for transcription of nearby genes in the context of
acetylated enhancers27. Our findings suggest that this is not true
in the context of deacetylated enhancers, where H3K4me2/me1
appears to provide an enhancer activation memory that has
impact on gene expression. Our observations are consistent with
evidence that H3K4me2 deposition is dependent on transcription
at enhancers, and that enhancer RNA transcripts correlate with
the expression of nearby genes28. The exact contexts in which
H3K4me2/me1 can drive gene expression and the mechanisms
employed will require further studies.
We find that in addition to RAR motifs, LSD1-regulated
enhancers are also enriched for FOXA and GATA motifs (Sup-
plementary Data 15) and that FOXA1, FOXA2, GATA4, and
GATA6 binding is enriched at LSD1-occupied enhancers (Sup-
plementary Fig. 5b). FOXA1/2 and GATA4/6 have known
functions in early pancreas development29–31. This indicates that
the regulation of early pancreatic enhancers requires collaborative
interactions of signal-dependent RARs with other TFs that reg-
ulate cell identity. We have previously shown that recruitment of
FOXAs to pancreas enhancers precedes pancreas induction, and
occurs prior to the addition of RA during hESC differentiation5.
Before RA is added, FOXA-occupied pancreatic enhancers are
poised. Combined with our present findings, this suggests that RA
induces the pancreatic lineage by binding to RARs that act upon a
set of primed enhancers established by FOXAs and other lineage-
determining TFs. FOXAs have previously been shown to broadly
prime enhancers of multiple gut tube-derived organs, including
liver and lung5. While pancreas induction requires RA, lung and
liver induction depend on BMP or BMP and WNT signalling,
respectively. Therefore, collaboration between signal-dependent
TFs and lineage-determining TFs, such as FOXAs, could be a
broadly used mechanism to specify different organ lineages from
a field of multipotent progenitors. Such mechanism is consistent
with the importance of niche signals for specifying progenitor
subdomains during development.
One open question is whether the here-described mechanism
for LSD1-mediated enhancer silencing is limited to RA-
dependent enhancers or could operate also in the context of
other signal-dependent enhancers. LSD1 has been shown to
reside in transcriptional complexes with signal-dependent TFs of
numerous signalling pathways, including the Notch, Wnt, and
multiple nuclear hormone receptor signalling pathways32–34.
Similar to RARs, which associate with HATs upon RA binding21,
the Notch intracellular domain facilitates recruitment of HATs to
Notch-responsive enhancers in the presence of ligand, and β-
catenin recruits HATs when the Wnt signalling pathway is
activated35,36. It is therefore conceivable that LSD1 limits the
duration of a transcriptional response at these enhancers in a
similar manner as shown in this study for RA-responsive
enhancers. Such unified mechanism for LSD1 function would
explain why LSD1 activity is required in numerous development
contexts throughout phylogeny37–41.
Methods
Cell lines. CyT49 embryonic stem cells were maintained in DMEM F12 (without
L-glutamine; VWR)+ 10% knockout serum replacement (KSR; Thermo Fisher
Scientific), 1% non-essential amino acids (NEAA; Thermo Fisher Scientific), 1%
GlutaMAX (Thermo Fisher Scientific), 0.2% β-mercaptoethanol (Thermo Fisher
Scientific) and 1% penicillin–streptomycin (Thermo Fisher Scientific). HEK293T
were maintained in DMEM F12 containing 100 units/mL penicillin and 100 mg/
mL streptomycin sulfate supplemented with 10% foetal bovine serum (FBS).
Animals. Pdx1-Cre, Pdx1-CreERTM42, Lsd1flox37, and Rosa26-eYFP43 mouse strains
have been described previously. Lsd1Δpan mice were generated by crossing Pdx1-
Cre and Lsd1flox mice. Conditional Lsd1 knockouts were generated by crossing
Pdx1-CreERTM and Lsd1flox mice. Tamoxifen (Sigma) was dissolved in corn oil
(Sigma) at 10 mg/mL, and a single dose of 3.5 mg/40 g or 4.5 mg/40 g body weight
was administered by intraperitoneal injection at embryonic day (e) 10.5 or e12.5,
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respectively. Control mice were LSD1+/+ littermates carrying the Pdx1-Cre or the
Pdx1-CreERTM transgene. Midday on the day of vaginal plug appearance was
considered embryonic day (e) 0.5. All animal experiments were approved by the
Institutional Animal Care and Use Committees of the University of California, San
Diego. The numbers of animals studied per genotype are indicated within each
experiment. The sex of Lsd1Δpan embryos and newborn pups was not determined.
Lsd1Δpan mice were not viable for more than 3–5 days after birth.
Human tissue. Human foetal pancreas donor tissue was obtained from the Birth
Defects Research Laboratory of the University of Washington. Cadaveric adult
pancreata used in this study were from non-diabetic donors and were acquired
through the Network for Pancreatic Organ Donors with Diabetes (nPOD)43.
Protein expression was analysed in nPOD donors: LSD1 and GCG in #6140 (38-
year-old male); LSD1 and CHGA in #6160 (22-year-old male); LSD1 and SST in
6178 (25-year-old female); and LSD1, INS and GCG in 6179 (21-year-old female).
All studies for use of foetal and adult human tissue were approved by the Insti-
tutional Review Board of the University of California, San Diego. Informed consent
was obtained for use of human samples.
Pancreatic endocrine differentiation of human embryonic stem cells (hESCs).
Pancreatic differentiation was performed as previously described5,12,14. Briefly, a
suspension-based culture format was used to differentiate cells in aggregate form.
Undifferentiated aggregates of hESCs were formed by re-suspending dissociated
cells in hESC maintenance medium at a concentration of 1 × 106 cells/mL and
plating 5.5 mL per well of the cell suspension in 6-well ultra-low attachment plates
(Costar). The cells were cultured overnight on an orbital rotator (Innova2000, New
Brunswick Scientific) at 95 rpm. After 24 h the undifferentiated aggregates were
washed once with RPMI medium and supplied with 5.5 mL of day 0 differentiation
medium. Thereafter, cells were supplied with the fresh medium for the appropriate
day of differentiation (see below). Cells were continually rotated at 95 rpm, or 105
rpm on days 4 through 8, and no media change was performed on day 10. Both
RPMI (Mediatech) and DMEM High Glucose (HyClone) medium were supple-
mented with 1X GlutaMAX™ and 1% penicillin/streptomycin. Human activin A,
mouse Wnt3a, human KGF, human noggin, and human EGF were purchased from
R&D systems. Other added components included FBS (HyClone), B-27® supple-
ment (Life Technologies), Insulin-Transferrin-Selenium (ITS; Life Technologies),
TGFβ R1 kinase inhibitor IV (EMD Bioscience), KAAD-Cyclopamine (KC; Tor-
onto Research Chemicals), and the retinoic receptor agonist TTNPB (RA; Sigma
Aldrich). Day-specific differentiation media formulations were as follows: Days 0
and 1: RPMI+ 0.2% (v/v) FBS, 100 ng/mL Activin, 50 ng/mL mouse Wnt3a,
1:5000 ITS. Days 1 and 2: RPMI+ 0.2% (v/v) FBS, 100 ng/mL Activin, 1:5000 ITS.
Days 2 and 3: RPMI+ 0.2% (v/v) FBS, 2.5 mM TGFβ R1 kinase inhibitor IV, 25
ng/mL KGF, 1:1000 ITS. Days 3–5: RPMI+ 0.2% (v/v) FBS, 25 ng/mL KGF, 1:1000
ITS. Days 5–8: DMEM+ 0.5X B-27® Supplement (contains ~0.1 mg/L of retinol,
all trans), 3 nM TTNPB, 0.25 mM KAAD-Cyclopamine, 50 ng/mL Noggin. Days
8–12: DMEM/B-27, 50 ng/mL KGF, 50 ng/mL EGF.
LSD1 inhibition during pancreatic differentiation. Early inhibition of LSD1
(LSD1iearly) was performed by addition of the irreversible LSD1 inhibitor tra-
nylcypromine (TCP) to cell culture wells on days 7, 8 and 9 at a final concentration
of 0.5 µM. Late inhibition of LSD1 (LSD1ilate) was performed by addition of TCP
to cell culture wells on days 10, 11 and 12 at a final concentration of 0.5 µM.
Additional LSD1 inhibitors used to perform LSD1iearly and LSD1ilate experiments
were SP2509 (Selleck Chemicals), GSK-LSD1 (Sigma) and GSK2879552 (Che-
mietek); and experiments were performed in the same way as with TCP, at a final
concentrations of 1 μM.
Alteration of retinoic acid treatment during pancreatic differentiation.
Extended retinoic acid (RA) treatment (RAextended) was performed by addition of
the RA analogue TTNPB to cell culture wells on days 8 and 9 at a final con-
centration of 3 nM. Late RA treatment (RAlate) was performed by addition of
TTNPB to cell culture wells on days 10 and 11 at a final concentration of 3 nM.
Chromatin immunoprecipitation sequencing. Chromatin Immunoprecipitation
Sequencing (ChIP-seq) experiments for histone modifications were performed on
day 10 with no TCP treatment or after TCP treatment (treatment on days 7, 8, and
9). ChIP-seq experiments for LSD1 were conducted on day 5 (GT stage) day 7
(PP1 stage) and day 10 (PP2 stage) without addition of TCP. ChIP-seq was per-
formed using the ChIP-IT High-Sensitivity kit (Active Motif) according to the
manufacturer’s instructions. Briefly, for each cell stage and condition analysed, 5-
10 ×106 cells were harvested and fixed for 15 min in an 11.1% formaldehyde
solution. Cells were lysed and homogenised using a Dounce homogeniser and the
lysate was sonicated in a Bioruptor® Plus (Diagenode), on high for 3 × 5 min (30 s
on, 30 s off). Between 10 and 30 µg of the resulting sheared chromatin was used for
each immunoprecipitation. Equal quantities of sheared chromatin from each
sample were used for immunoprecipitations carried out at the same time. 4 µg of
antibody were used for each ChIP-seq assay. Antibodies used were: rabbit anti-
H3K27ac (Active Motif); rabbit anti-H3K4me1 (Abcam); rabbit anti-H3K4me2
(Millipore); rabbit anti-LSD1 (Abcam); goat anti-FOXA1 (Abcam); goat anti-
FOXA2 (Santa Cruz); goat anti-GATA4 (Santa Cruz); mouse anti-GATA6 (Santa
Cruz); rabbit anti-HNF6 (Santa Cruz); and rabbit anti-RXRA (Santa Cruz).
Chromatin was incubated with primary antibodies overnight at 4 °C on a rotator
followed by incubation with Protein G agarose beads for 3 h at 4 °C on a rotator.
Reversal of crosslinks and DNA purification were performed according to the
ChIP-IT High-Sensitivity instructions, with the modification of incubation at 65 °C
for 2–3 h, rather than at 80 °C for 2 h. Sequencing libraries were constructed using
KAPA DNA Library Preparation Kits for Illumina® (Kapa Biosystems) and library
sequencing was performed on a HiSeq 4000 System (Illumina®) with single-end
reads of 50 base pairs (bp). Both library construction and sequencing were per-
formed by the Institute for Genomic Medicine (IGM) core research facility at the
University of California at San Diego (UCSD). Two replicates from independent
hESC differentiations were generated for each ChIP-seq experiment, except for
RXR where only one dataset was generated.
Chromatin immunoprecipitation sequencing data analysis. Single-end 50-bp
ChIP-seq reads were mapped to the human genome consensus build (hg19/
GRCh37) and visualised using the UCSC Genome Browser44. Bowtie 2, version
2.2.745 was used to map data to the genome and unmapped reads were discarded.
SAMtools46 was used to remove duplicate sequences and HOMER47 was used to
call peaks using default parameters and to generate tag density plots. Stage- and
condition-matched input DNA controls were used as background when calling
peaks. The BEDtools48 suite of programs was used to analyze whether certain peaks
overlapped with other peaks or modified histone regions. Differential peak analysis
using HOMER, with default parameters, identified enhancer dynamics between the
PP1 to PP2 stage and classify LSD1-bound enhancers into the different enhancer
groups (G1, G2 and G3). Each ChIP-seq analysis was performed with two biolo-
gical replicates, except H3K4me2 at GT, for which pseudo-replicates were gener-
ated. The first replicate was analysed and correlated with the appropriate second
replicate. Pearson correlations between replicates are listed in Supplementary
Table 1.
RNA Isolation and sequencing (RNA-seq) and qRT-PCR. RNA was isolated
from cell samples using the RNeasy® Micro Kit (Qiagen) according to the manu-
facturer instructions. For each cell stage and condition analysed between 0.1 and
1 × 106 cells were collected for RNA extraction. For qRT-PCR, cDNA synthesis was
first performed using the iScript™ cDNA Synthesis Kit (Bio-Rad) and 500 ng of
isolated RNA per reaction. qRT-PCR reactions were performed in triplicate with
10 ng of template cDNA per reaction using a CFX96™ Real-Time PCR Detection
System and the iQ™ SYBR® Green Supermix (Bio-Rad). PCR of the TATA binding
protein (TBP) coding sequence was used as an internal control and relative
expression was quantified via double delta CT analysis. For RNA-seq, stranded,
single-end sequencing libraries were constructed from isolated RNA using the
TruSeq® Stranded mRNA Library Prep Kit (Illumina®) and library sequencing was
performed on a HiSeq 4000 System (Illumina®) with single-end reads of 50-bp.
Both library construction and sequencing were performed by the IGM core
research facility at UCSD. A complete list of RT-qPCR primer sequences can be
found in Supplementary Table 2.
RNA-seq data analysis. Single-end 50-bp reads were mapped to the human
genome consensus build (hg19/GRCh37) using the Spliced Transcripts Alignment
to a Reference (STAR) aligner49. Tag directories were constructed from STAR
outputs and normalised gene expression (fragments per kilobase per million
mapped reads; FPKM) for each sequence file was determined using HOMER47.
HOMER was used to annotate all RefSeq genes with FPKM values and to invoke
the R package DESeq250 for differential expression analysis. Each RNA-seq analysis
was performed on at least two biological replicates with DESeq2, using the built-in
option to account for batch effects.
Assignment of enhancer target genes and motif enrichment analysis.
Enhancer target genes were assigned using BEDtools to identify transcription start
sites (TSSs) located ±100 kb from LSD1-bound enhancers (groups G1, G2 and G3).
HOMER47 was used to identify transcription factor (TF) binding motifs enriched
in the G1 enhancer group versus the G2 and G3 groups. G2 and G3 enhancer peak
files were merged and set as the background. G1 enhancers associated with one or
more genes with FPKM ≥ 1 at the PP1 stage were used for motif analysis. Ana-
logous motif enrichment analysis was conducted at G2 and G3 enhancers versus
the entire genome, excluding G1, G2, and G3 regions.
Flavin adenine dinucleotide measurements. Flavin adenine dinucleotide (FAD)
on hESC-derived cells was isolated with the FAD Assay Kit (Abcam, ab204710).
Cell lysates were deproteinated using perchloric acid and FAD was quantified using
the colorimetric assay according to the manufacturer’s instructions. The isolation
procedure was performed in triplicate with one to two million cells on differ-
entiation days 0, 2, 5, 10, and 13. FAD measurements were performed simulta-
neously and normalized to protein concentration determined by the Micro BCA
Protein Assay Kit (Thermo Scientific, 23235).
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Immunofluorescence analysis. Cell aggregates derived from hESCs were allowed
to settle in microcentrifuge tubes and washed twice with PBS before fixation with
4% paraformaldehyde (PFA) for 30 min at room temperature. Dissected
e10.5–e13.5 mouse embryos, e15.5—postnatal day (P) 0 pancreata, and pancreata
from 3-month-old mice were fixed in 4% PFA in PBS for 30 min, 3 h, and over-
night, respectively. Fixed samples were washed twice with PBS and incubated
overnight at 4 °C in 30% (w/v) sucrose in PBS. Samples were then loaded into
disposable embedding molds (VWR), covered in Tissue-Tek® O.C.T. Sakura®
Finetek compound (VWR) and flash frozen on dry ice to prepare frozen blocks.
The blocks were sectioned at 10 µm and sections were placed on Superfrost Plus®
(Thermo Fisher) microscope slides and washed with PBS for 10 min. Slide-
mounted cell sections were permeabilised and blocked with blocking buffer, con-
sisting of 0.15% (v/v) Triton X-100 (Sigma) and 1% (v/v) normal donkey serum
(Jackson Immuno Research Laboratories) in PBS, for 1 h at room temperature.
Slides were then incubated overnight at 4 °C with primary antibody solutions. The
following day slides were washed five times with PBS and incubated for 1 h at room
temperature with secondary antibody solutions. Cells were washed five times with
PBS before coverslips were applied.
All antibodies were diluted in blocking buffer at the ratios indicated below.
Primary antibodies used were: goat anti-carboxypeptidase A1 (Cpa1) (1:1000
dilution, R&D systems); goat anti-ghrelin (Ghrl) (1:300 dilution, Santa Cruz); goat
anti-glucagon (Gcg) (1:1000 dilution, Santa Cruz); goat anti-osteopontin (Opn)
(1:300 dilution, R&D systems); guinea pig anti-Ngn3 (1:1000,51); goat anti-PDX1
(1:500 dilution, Abcam); guinea pig anti-insulin (INS) (1:500 dilution, Dako);
mouse anti-glucagon (GCG) (1:500 dilution, Sigma); rabbit anti-somatostatin
(SST) (1:500 dilution, Dako); mouse anti-NKX6.1 (1:300 dilution, Developmental
Studies Hybridoma Bank); rabbit anti-amylase (Amy) (1:500 dilution, Sigma);
rabbit anti-chromogranin A (ChgA) (1:1000 dilution, Dako); rabbit anti-LSD1
(1:500 dilution, Abcam); rabbit anti-Phospo-Histone3 (Ser10) (pHH3) (1:1000
dilution, Cell Signaling); rabbit anti-polypeptide Y (Ppy) (1:1000 dilution, Dako);
rabbit anti-Ptf1a (1:500 dilution, BCBC); rabbit anti-SOX9 (1:1000 dilution,
Millipore); rat anti-E-cadherin (Cdh1) (1:300 dilution, Sigma); rat anti-EpCAM
(1:100, DSHB # G8.8); sheep anti-NGN3 (1:300, R&D Systems). Secondary
antibodies against sheep, rabbit, goat, mouse, rat, and guinea pig were Alexa488-,
Cy3- and Cy5-conjugated donkey antibodies and were used at dilutions of 1:1000,
1:2000, and 1:250, respectively (Jackson Immuno Research Laboratories). Cell
nuclei were stained with Hoechst 33342 (1:3000, Invitrogen). TUNEL staining was
performed using the ApopTag® Plus Peroxidase In Situ Apoptosis Kit (Millipore).
Representative images were obtained with a Zeiss Axio-Observer-Z1 microscope
equipped with a Zeiss ApoTome and AxioCam digital camera. Figures were
prepared in Adobe Creative Suite 5.
Flow cytometry analysis. Cell aggregates derived from hESCs were allowed to
settle in microcentrifuge tubes and washed with PBS. Cell aggregates were incu-
bated with Accutase® at room temperature until a single-cell suspension was
obtained. Cells were washed with 1 mL ice-cold flow buffer comprised of 0.2% BSA
in PBS and centrifuged at 200 × g for 5 min. BD Cytofix/Cytoperm™ Plus Fixation/
Permeabilization Solution Kit was used to fix and stain cells for flow cytometry
according to the manufacturer’s instructions. Briefly, cell pellets were re-suspended
in ice-cold BD Fixation/Permeabilization solution (300 µL per microcentrifuge
tube). Cells were incubated for 20 min at 4 °C. Cells were washed twice with 1 mL
ice-cold 1X BD Perm/Wash™ Buffer and centrifuged at 10 °C and 200 × g for 5 min.
Cells were re-suspended in 50 µL ice-cold 1X BD Perm/Wash™ Buffer containing
diluted antibodies, for each staining performed. Cells were incubated at 4 °C in the
dark for 1 h. Cells were washed with 1.25 mL ice-cold 1X BD Wash Buffer and
centrifuged at 200 × g for 5 min. Cell pellets were re-suspended in 300 µL ice-cold
flow buffer and analysed in a FACSCanto™ (BD Biosciences). Antibodies used for
flow cytometry: PE-conjugated anti-PDX1 (1:20 dilution, BD Biosciences); Alex-
aFluor® 647-conjugated anti-NKX6.1 (1:20 dilution, BD Biosciences); PE-
conjugated anti-INS (1:50 dilution, BD Biosciences). Flow cytometry data was
processed using FlowJo v10 software.
Generation of LSD1 shRNA lentiviruses. To generate shRNA expression vectors,
shRNA guide sequences were placed under the control of the human U6 pol III
promoter in the pLKO.1 backbone (Addgene, plasmid #10878). Small hairpin
sequences are listed in Supplementary Table 3.
High-titer lentiviral supernatants were generated by co-transfection of the
shRNA expression vector and the lentiviral packaging construct into
HEK293T cells as described12. Briefly, shRNA expression vectors were co-
transfected with the pCMV-R8.74 (Addgene, #22036) and pMD2.G (Addgene,
#12259) expression plasmids into HEK293T cells using a 1 mg/ml PEI solution
(Polysciences). Lentiviral supernatants were collected at 48 h and 72 h after
transfection. Lentiviruses were concentrated by ultracentrifugation for 120 min at
19,500 rpm using a Beckman SW28 ultracentrifuge rotor at 4 °C.
Transduction of hESC endodermal lineage intermediates. Differentiation
toward the pancreatic progenitor cell stage was initiated as described. At day 6 of
differentiation, cells were dissociated with Accutase, washed in PBS+ 0.02% BSA
and counted. Cells were then distributed onto a 6 well plate at a density of 5 million
cells per well. Concentrated lentivirus was then added at 1 µL/mL media, as well as
8 µg/mL polybrene, 10 µM Rock Inhibitor, and 5 units/mL heparin. Cells were then
re-aggregated at 100 rpm. After 6 h, viral media was replaced with fresh day 6
differentiation media. Differentiation was then continued as described, and cells
were collected for analysis at day 13.
RNAscope. Mouse embryos at e12.5 were fixed in 4% PFA at 4 °C overnight,
embedded in OCT (Sakura Finetek), frozen, and sectioned at 10 µm. Serial sections
were prepared as described in the “Immunofluorescence analysis” section. The
expression of mouse HoxA1 transcripts was detected using the RNAscope Probe-
Mm-Hoxa1 #542391, Multiplex Fluorescent Reagent Kit v2 (#323100, Advanced
Cell Diagnostics) and Opal 570 Reagent Pack (Akoya Biosciences #FP1488001KT)
according to the manufacturers’ recommendations, with the following specifics:
target retrieval was omitted, slides received a 30 min treatment with Protease IV
and Opal 570 fluorophore and DAPI was diluted at 1:1500. Images were captured
with a Zeiss Apotome microscope.
Gene ontology. Gene ontology analysis was performed using Metascape (http://
metascape.ncibi.org) with the default parameters.
Principle component analysis. For all samples, FPMKs for total transcriptome
were calculated as described above. Genes were then filtered for FPKMs greater
than or equal to one, and genes showing the top 25% median absolute deviation
(MAD) were selected. Based on these values, PCA plots were generated using the
PRComp package in R.
Morphometric analysis and cell counting. At e12.5, every pancreas section was
analysed from a minimum of three embryos per genotype, while every fifth pan-
creas section was analysed at e15.5. For determination of total pancreatic epithelial
area, E-cadherin+ area per section was measured using ZEN Digital Imaging for
Light Microscopy software (ZEISS), which was calibrated to calculate values in
μm2. The number of marker+ cells was determined by counting every marker
+/DAPI+ cell in each section. The number of marker+ cells per section was
subsequently divided by the total epithelial area of the section and expressed as
marker+ cells/μm2. All values are shown as mean ± standard error of the mean
(SEM); p-values calculated using unpaired Student’s t-test; p < 0.05 was considered
significant.
Experimental comparisons. All experiments were independently repeated at least
twice. Results are shown as mean ± SEM. Statistical analyses were conducted using
GraphPad Prism 6 and R.
Differential gene expression analysis. The DESeq2 Bioconductor package for R
was used to calculate gene expression changes. Adjusted p-values < 0.05 and
log2(fold-change) ≥1.5 were considered significantly different.
Permutation-based significance. A random sampling approach (10,000 itera-
tions) was used to obtain null distributions for enrichment analyses, in order to
obtain p-values. Null distributions for enrichment of enhancers for gene sets were
obtained by randomly shuffling enhancer regions using BEDtools and overlapping
with nearby genes. P-values < 0.05 were considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its Supplementary Information files or from the corresponding author
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